Pharma giants push for US tariff relief through NHS price cap deal.

Pharmaceutical companies, including AstraZeneca and GSK, are hoping that a deal between the UK and the US will address a controversial medicine tax that makes Britain "uninvestable." The tax, which caps drug prices and requires companies to pay rebates to the NHS, has led to high repayment rates, making it difficult for drugmakers to invest in research and development. Industry sources say that the rebate is likely to be wrapped into ongoing US tariff talks.